Abstract
Although warfarin is effective, it has a narrow therapeutic interval with difficult dose adjustment, and low TTR values (time within the therapeutic range <50%) are associated with risk of adverse events and, consequently, broad public spending. Studies show that clinical and genetic factors influence warfarin dose variability. Our group developed a pharmacogenetic algorithm estimati…